IDS and mucopolysaccharidosis type 2: We have rigorously examined the relationship between anti-idursulfase Ab status, genotype, and safety and efficacy outcomes for MPS II patients aged ≤5 years at screening who were treated with idursulfase as part of study HGT-ELA-038.